MindBio Therapeutics Corp.
MBIO
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -200.48% |
| Total Revenue | -- | -- | -- | -- | -200.48% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -200.48% |
| SG&A Expenses | 1,694.87% | 909.59% | 463.56% | 212.46% | -87.68% |
| Depreciation & Amortization | -9,333.33% | -318.53% | 400.00% | 350.00% | -106.06% |
| Other Operating Expenses | -3.93% | -3.93% | -3.93% | -44.20% | -44.20% |
| Total Operating Expenses | 1,571.61% | 784.84% | 441.69% | 193.39% | -87.13% |
| Operating Income | -576.45% | -560.36% | -438.71% | -191.98% | 60.80% |
| Income Before Tax | -351.31% | -868.91% | -1,339.62% | -563.20% | 55.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -351.31% | -868.91% | -1,339.62% | -563.20% | 55.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -168.75% | -237.50% | 100.00% | -150.00% | 1,500.00% |
| Net Income | -352.94% | -875.52% | -1,336.26% | -563.65% | 56.12% |
| EBIT | -576.45% | -560.36% | -438.71% | -191.98% | 60.80% |
| EBITDA | -947.15% | -4,564.79% | -1,092.19% | -687.62% | -186.49% |
| EPS Basic | 13.12% | -188.40% | -366.97% | -179.35% | -18.06% |
| Normalized Basic EPS | -64.06% | -117.04% | -242.01% | -87.53% | 24.17% |
| EPS Diluted | 13.12% | -188.40% | -366.97% | -179.35% | -18.06% |
| Normalized Diluted EPS | -30.74% | -74.44% | -242.01% | -87.53% | 24.17% |
| Average Basic Shares Outstanding | 914.38% | 232.05% | 142.64% | 87.24% | -35.14% |
| Average Diluted Shares Outstanding | 1,141.76% | 460.88% | 142.64% | 87.24% | -35.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |